Based on the dynamic analysis of the specific roles and interactions of key molecules such as HIF-1α and mTOR in different stages and cell types during sepsis, the individualized treatment window should be accurately defined, and then the targeted intervention of the immune-metabolic network should be realized from “empirical” to “precision”-that is, specifically inhibiting inflammatory metabolism in the early hyper-inflammatory stage and effectively repairing cellular energy exhaustion in the late immunosuppressive stage to avoid exacerbating the condition due to incorrect medication. The gene discussed is MTOR; the disease is Sepsis.